Cargando…

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations

Adenovirus vectored vaccines have entered global use during the COVID-19 pandemic, and are in development for multiple other human and veterinary applications. An attraction of the technology is the suitability of the vaccines for storage at 2–8 °C for months. Widely used COVID-19 vaccine ChAdOx1 nC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berg, Adam, Wright, Daniel, Dulal, Pawan, Stedman, Anna, Fedosyuk, Sofiya, Francis, Michael J., Charleston, Bryan, Warimwe, George M., Douglas, Alexander D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623940/ https://www.ncbi.nlm.nih.gov/pubmed/34835180 http://dx.doi.org/10.3390/vaccines9111249

Ejemplares similares

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine
por: Grobusch, Martin P., et al.
Publicado: (2021)

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
por: Stedman, Anna, et al.
Publicado: (2019)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1
por: Patel, Shreena Umit, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

The COVID‐19 vaccine ChAdOx1‐S is not contaminated with sulfated glycosaminoglycans
por: Alban, Susanne, et al.
Publicado: (2022)

Prolonged febrile illness following first dose of ChAdOx1
por: Caruana Dingli, Michael, et al.
Publicado: (2023)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination
por: Suan, Dan, et al.
Publicado: (2022)

Myelin Oligodendrocyte Glycoprotein-Associated Disorders Post-ChAdOx1 Vaccination
por: Maramattom, Boby Varkey
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Central nervous system adverse events after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2022)

De novo psoriasis induced by ChAdOx1-S COVID 19 vaccine()
por: Zaiem, Ahmed, et al.
Publicado: (2022)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
por: de Laat, Bas, et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Two flares of Still’s disease after two doses of the ChAdOx1 vaccine
por: Roongta, Rashmi, et al.
Publicado: (2022)

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
por: Baker, Alexander T., et al.
Publicado: (2021)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
por: Garibashvili, Tamara, et al.
Publicado: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
por: Krutzke, Lea, et al.
Publicado: (2022)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
por: Dicks, Matthew D. J., et al.
Publicado: (2015)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
por: Kim, Jinnam, et al.
Publicado: (2023)

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
por: Al Bahrani, Salma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7krt26oo8uf7i3o2g06q5vkhun